The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 35.00 (1.82%)
Spread: 2.00 (0.102%)
Open: 1,937.00
High: 1,977.00
Low: 1,931.00
Prev. Close: 1,925.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hikma Pharmaceuticals director buys-in after full-year results

Thu, 14th Mar 2019 16:24

(Sharecast News) - One of Hikma Pharmaceuticals's directors picked-up some shares in the company the day after its latest full-year numbers.On Thursday, Dr. Pamela Kirby, a non-executive director at the non-branded generic and in-licensed pharmaceutical products maker, purchased 1,500 shares, on the market, at 1,586p apiece for a total transaction amount of £23,790.The day before, Hikma had posted a 7% increase in full-year 2018 core revenues to $2.08bn with core operating profit up by 19% at $460m, but its sales were 1% below the average analyst forecast and profit was 2% light.Core basic earnings per share, however, increased 31% to 137.8 cents, beating the consensus by 2% due to lower finance charges, while cash-flow from operating activities of $430m down from $443m.Her purchase followed others by the executive chairman and vice-chairman, Said Darwazah and Mazen Darwazah, respectively, also the day before.Analysts at Numis described the company's results as "strong" but said consensus estimates might be set for "modest downgrades"."The shares aren't particularly cheap and conditions in US generics remain volatile and with the shares trading on 11 times's EV/EBITDA we stick with the 'hold' rating."Top Director BuysHikma Pharmaceuticals (HIK)Director name: Kirby,PamelaAmount purchased: 1,500 @ 1,586.00pValue: £23,790.004d Pharma (DDDD)Director name: Stevenson,Alexander JamesAmount purchased: 24,896 @ 91.50pValue: £22,779.84Haydale Graphene Industries (HAYD)Director name: Humm,Roger JamesAmount purchased: 841,432 @ 2.00pValue: £16,828.64Haydale Graphene Industries (HAYD)Director name: Broadbent,KeithAmount purchased: 500,000 @ 2.00pValue: £10,000.00Haydale Graphene Industries (HAYD)Director name: Banks,David Amount purchased: 500,000 @ 2.00pValue: £10,000.00Haydale Graphene Industries (HAYD)Director name: Redman-Thomas,LauraAmount purchased: 375,000 @ 2.00pValue: £7,500.004d Pharma (DDDD)Director name: Peyton,Duncan Joseph Amount purchased: 6,770 @ 92.00pValue: £6,228.40React Group (REAT)Director name: Joyce,MichaelAmount purchased: 2,000,000 @ 0.27pValue: £5,340.00React Group (REAT)Director name: Joyce,MichaelAmount purchased: 1,000,000 @ 0.27pValue: £2,670.00Kcom Group (KCOM)Director name: Bielby,AnnaAmount purchased: 217 @ 69.18pValue: £150.12Zotefoams (ZTF)Director name: Stirling,DavidAmount purchased: 25 @ 599.00pValue: £149.75Zotefoams (ZTF)Director name: McGrath ,Gary Amount purchased: 25 @ 599.00pValue: £149.75Top Director SellsRecord (REC)Director name: Wood-Collins,JamesAmount sold: 146,716 @ 28.70pValue: £42,107.49
More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.